In this episode, host Petros Grivas, MD, PhD, FASCO, welcomes Ryan Cassaday, MD, a leukemia researcher and physician at Fred Hutch Cancer Center and a professor at the University of Washington School of Medicine, to discuss his path to oncology, recent advances in acute lymphoblastic leukemia (ALL) treatment and the importance of clinical trials and community partnerships. Listen to learn how emerging therapies and innovative research are helping improve outcomes and expand access to care for patients with ALL.
Key topics
Cassaday's career path and what inspired his interest in oncology and blood cancers
His research at Fred Hutch focused on novel immunotherapy- and chemotherapy-based approaches for ALL
The impact of bispecific T-cell engager therapies, including blinatumomab, and the potential of new formulations
Innovative clinical trial designs, including dose-adjusted EPOCH combined with monoclonal antibody therapies
The role of community partnerships in caring for patients with complex leukemia diagnoses
Opportunities and challenges in coordinating inpatient and outpatient leukemia care across large geographic regions
Fred Hutch's leadership in cellular therapies, stem cell transplantation and care for patients from around the world
Future directions in ALL treatment aimed at improving cure rates while reducing treatment-related burden
YouTube | Spotify | Apple Podcasts | Libsyn | Amazon Music
More episodes
- Episode 18: Dr. Annemarie Shepherd on proton therapy, clinical trials and the future of radiation oncology
- Episode 17: Dr. Lara Davis on sarcoma care, clinical trials and team-based treatment
- Episode 16: Dr. Marco Mielcarek on making blood and marrow transplants safer and more accessible
- Episode 15: Exploring neuro-oncology leadership and innovation with Dr. Vyshak Venur
- Episode 14: Dr. Sara Hurvitz on clinical trials, multidisciplinary care and leadership in oncology
